News
FEMY
2.380
-4.03%
-0.100
Weekly Report: what happened at FEMY last week (0914-0918)?
Weekly Report · 09/21 09:24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/16 12:06
Femasys Expands Fertility Portfolio Adoption Through Minnesota Women's Care
NASDAQ · 09/15 13:25
Femasys announces Minnesota Women’s Care to implement FemVue
TipRanks · 09/15 13:20
Weekly Report: what happened at FEMY last week (0907-0911)?
Weekly Report · 09/14 09:26
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
NASDAQ · 09/11 16:06
Femasys Partners With CapexMD To Expand Access To FemaSeed Fertility Portfolio
NASDAQ · 09/09 16:00
Femasys partners with CapexMD to expand patient access
TipRanks · 09/09 13:20
Weekly Report: what happened at FEMY last week (0831-0904)?
Weekly Report · 09/07 09:24
Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock
Benzinga · 09/03 21:10
Weekly Report: what happened at FEMY last week (0824-0828)?
Weekly Report · 08/31 09:26
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 08/28 17:05
Weekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal
NASDAQ · 08/28 14:42
Femasys Partners With UNC Health To Expand Fertility Care Access
NASDAQ · 08/26 13:48
Femasys announces fertility partnership with UNC Health
TipRanks · 08/26 13:05
Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations
Benzinga · 08/26 13:04
Weekly Report: what happened at FEMY last week (0817-0821)?
Weekly Report · 08/24 09:26
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
Benzinga · 08/19 17:36
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 08/19 17:05
Femasys announces FDA approval of FemBloc modular premarket approval application
TipRanks · 08/19 13:16
More
Webull provides a variety of real-time FEMY stock news. You can receive the latest news about FEMASYS INC through multiple platforms. This information may help you make smarter investment decisions.
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.